Literature DB >> 11278558

Role of p53 in HER2-induced proliferation or apoptosis.

P Casalini1, L Botta, S Menard.   

Abstract

HER2 oncogene overexpression has been associated either with proliferation or differentiation and apoptosis. The role of p53 on these different chances was investigated. Wild type (wt) p53-IGROV1 cells showed growth inhibition and apoptosis after HER2 transfection, whereas no anti-proliferative effect was observed in its mutated p53 sub-line unless wt p53 was cotransfected with HER2. Stable HER2 transfectants derived from wt p53 line treated with heregulin-beta1 or epidermal growth factor showed a decrease in proliferation due to a G(2)/M cell cycle block despite normal mitogen-activated protein kinase activation. In these HER2 transfectants, c-Myc and p53 expression were increased, whereas MDM2 was dramatically down-modulated. By contrast, growth factors stimulation of HER2 transfectants with mutated-p53 induced progression through the cell cycle. Together, our data point to a regulatory role for p53 in HER2 signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278558     DOI: 10.1074/jbc.M009732200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells.

Authors:  Francesca Bianchi; Alessandra Magnifico; Clelia Olgiati; Nicola Zanesi; Yuri Pekarsky; Elda Tagliabue; Carlo Maria Croce; Sylvie Ménard; Manuela Campiglio
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

2.  BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Authors:  Britta Stordal; Kirsten Timms; Angela Farrelly; Danielle Gallagher; Steven Busschots; Mickaël Renaud; Julien Thery; Deborah Williams; Jennifer Potter; Thanh Tran; Greg Korpanty; Mattia Cremona; Mark Carey; Jie Li; Yang Li; Ozlem Aslan; John J O'Leary; Gordon B Mills; Bryan T Hennessy
Journal:  Mol Oncol       Date:  2013-01-31       Impact factor: 6.603

3.  A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors.

Authors:  Laura Menotti; Arianna Cerretani; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 4.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

5.  Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Takayuki Sugiyama; Robert D Kendig; Donna P Frazier; Mark C Willingham; Kazushi Inoue
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

6.  Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.

Authors:  Eleonora Gambini; Elisa Reisoli; Irene Appolloni; Valentina Gatta; Gabriella Campadelli-Fiume; Laura Menotti; Paolo Malatesta
Journal:  Mol Ther       Date:  2012-02-21       Impact factor: 11.454

7.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

8.  Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.

Authors:  Alicia A Goyeneche; Rubén W Carón; Carlos M Telleria
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

9.  TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells.

Authors:  Benedicte Stavik; Grethe Skretting; Ole Kristoffer Olstad; Marit Sletten; Magnus Dehli Vigeland; Per Morten Sandset; Nina Iversen
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.

Authors:  J Kupryjańczyk; R Madry; J Plisiecka-Hałasa; J Bar; E Kraszewska; I Ziółkowska; A Timorek; J Stelmachów; J Emerich; M Jedryka; A Płuzańska; I Rzepka-Górska; K Urbański; J Zieliński; J Markowska
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.